ALC · Alcon Inc.

Alcon's first quarter 2026 performance demonstrated solid top-line growth, with net sales increasing 10% on a reported basis to $2.7 billion, driven by strong uptake of new products such as Unity VCS and CS, PanOptix Pro, and Tryptyr. The Vision Care segment saw robust growth in Ocular health (+13% reported), while the Surgical segment benefited from a 27% surge in Equipment/other sales following the launch of the Unity platform. Geographically, the company noted continued competitive pressures in international markets for Implantables, which grew only 4% reported.

Profitability metrics showed a divergence between reported and core results. Reported operating income fell 38% to $292 million, primarily due to prior year gains on fair value remeasurements of investments in associated companies ($142 million) which were not repeated, alongside current period costs related to efficiency initiatives ($88 million) and impairment charges ($38 million). Conversely, core operating income rose 11% to $569 million, reflecting improved operating leverage and manufacturing efficiencies that offset incremental tariffs and increased R&D spending.

Management maintained its full-year 2026 outlook for net sales growth and core operating margin change but updated core diluted EPS growth guidance to a range of 10% to 13% on a constant currency basis, up from the prior range of 9% to 12%. The company also announced significant capital allocation actions, including a new $1.5 billion share repurchase authorization over three years and a dividend of CHF 0.28 per share. The company noted a full-year tariff impact, net of mitigating actions, of approximately $100 to $150 million.